Open Study of Madopar HBS, a New Formulation of Levodopa with Benserazide, in 13 Patients with Parkinson’s Disease and ‘On-Off’ Fluctuations
- 1 January 1987
- journal article
- clinical trial
- Published by S. Karger AG in European Neurology
- Vol. 27 (1) , 105-113
- https://doi.org/10.1159/000116204
Abstract
In a open study in 13 patients with Parkinson's disease with 'on-off' fluctuations, all (n = 3) or part (n = 10) of the usual intake of levodopa (with peripheral decarboxylase inhibitor) was replaced by Madopar HBS for 5-122 days (median 35). Time 'off' increased in 2 of the 3 monotherapy subjects. With combined therapy, time 'on' was increased in 6, unchanged in 2 and reduced in 2. However, 11 of the 13 patients complained of reduced predictability of clinical response with Madopar HBS. Only 4 of the 13 patients preferred to continue with combined standard plus HBS treatment; this continued treatment led to an increase in time 'on' in 3 and a decrease in involuntary movements in 3 patients. Two of these four patients benefited on both counts.Keywords
This publication has 0 references indexed in Scilit: